



## Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026 12:05 PM EDT

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Apr. 23, 2026-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 888.596.4144 (domestic) or 646.968.2525 (international or alternate), and Conference ID 6626692. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at <https://ir.harmonybiosciences.com/>.

### About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit [www.harmonybiosciences.com](http://www.harmonybiosciences.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260423924114/en/): <https://www.businesswire.com/news/home/20260423924114/en/>

### Harmony Biosciences Investor Contact:

Brennan Doyle  
484-566-3685  
[bdoyle@harmonybiosciences.com](mailto:bdoyle@harmonybiosciences.com)

### Harmony Biosciences Media Contact:

Cate McCanless  
202-641-6086  
[cmccanless@harmonybiosciences.com](mailto:cmccanless@harmonybiosciences.com)

Source: Harmony Biosciences Holdings, Inc.